
PhD student Jacob Williams works in the lab. engineering) Just add water therapeutics
Student- Jacob Williams
Photography by: Mark A. Philbrick/BYU Photo
Researchers at BYU have devised a system to speed up the process of making life-saving vaccines for new viruses.
Their concept is to create the biological machinery for vaccine production en masse, put it in a freeze-dried state and stockpile it around the country. Then, when a new virus hits, labs can simply add water to a “kit” to rapidly produce vaccines.
“You could just pull it off the shelf and make it,” said senior author Brad Bundy, associate professor of chemical engineering. “We could make the vaccine and be ready for distribution in a day.”
The research, published in Biotechnology Journal, demonstrates the ability to store the drug and vaccine-making machinery for more than a year.
Traditional systems to produce vaccines for pandemic influenza strains require heavy engineering and specialized equipment that only a few labs across the country have on hand. These traditional systems are also time-consuming, taking months to execute.
Bundy’s idea is a new angle on the emerging method of “cell-free protein synthesis,” a process that combines DNA to make proteins needed for drugs (instead of growing protein in a cell). His lab is creating a system where the majority of the work is done beforehand so vaccine kits can be ready to go and be activated at the drop of a dime.
“It will not only provide a quicker response to pandemics, but it will also make protein-based drugs more available to third-world countries where production and refrigerated storage can be problematic,” added William Pitt, a study coauthor and fellow BYU professor of chemical engineering.
While the team is now testing their version of the cell-free, recombinant DNA process for vaccine production, they’ve already successfully demonstrated it for at least one anti-cancer protein (onconase).
The researchers believe their method can significantly reduce investment of time and money towards future drug production and, in turn, reduce treatment expenses for patients.
“The drugs today are changing,” Bundy said. “The lifesaving cancer drugs we have now, the drugs for arthritis, the drugs with the greatest impact, are made out of proteins, not small chemical molecules. This method takes full advantage of that to provide a quicker, more personal response.”
Read more: BYU researchers speeding up process of making vaccines
The Latest on: Making vaccines
[google_news title=”” keyword=”Making vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Making vaccines
- I was one the first people to get a vaccine for breast cancer. It could save millions of lives worldwide.on June 2, 2023 at 2:45 am
Jennifer Davis volunteered for the trial of a new vaccine designed to prevent breast cancer. The mom was the very first person to receive the vaccine.
- Second RSV Vaccine Lands Approval for Older Adultson June 2, 2023 at 12:09 am
Approval of the unadjuvanted, bivalent RSV prefusion F protein vaccine (Abrysvo) follows an endorsement in March from FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC).
- Pfizer’s RSV Vaccine Wins FDA Approval on Heels of Regulatory Nod for GSKon June 1, 2023 at 3:12 pm
Pfizer’s Abrysvo is now approved for preventing illness caused by respiratory syncytial virus, or RSV, in adults 60 and older. The regulatory decision comes weeks after GSK won approval for its RSV ...
- In Another Victory Over RSV, a Second Vaccine for Adults Gets FDA Approvalon June 1, 2023 at 2:16 pm
Pfizer’s vaccine, the second to get FDA approval for RSV, is more than 85 percent effective at preventing severe disease caused by the common respiratory syncytial virus.
- RSV vaccine competition heats up as Pfizer’s shot for older adults gets FDA approvalon June 1, 2023 at 8:46 am
The FDA’s nod came just weeks after the agency gave the green light to GSK’s Arexvy, the first RSV vaccine approved for use in the U.S. Both vaccines are approved for adults 60 and over.
- FDA approves 2nd U.S. RSV vaccineon May 31, 2023 at 5:46 pm
The Food and Drug Administration on Wednesday approved Pfizer's vaccine against respiratory syncytial virus for people aged 60 and older, making it the second RSV shot authorized for use in the U.S.
- US FDA approves Pfizer's RSV vaccineon May 31, 2023 at 2:38 pm
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease ...
- Science finally figured out how to make effective RSV vaccines. Will seniors care?on May 27, 2023 at 12:10 pm
Both will likely be in use this fall, in time to protect seniors going into the next RSV season. So it’s tempting to think the fight against respiratory syncytial virus in older adults is about to ...
- mRNA Vaccines Could Revolutionize Agriculture, But They Need To Overcome One Big Hurdleon May 24, 2023 at 1:16 am
I am a researcher who has been making vaccines for a number of years, and I started studying mRNA vaccines before the pandemic started. My research on using mRNA vaccines for cattle respiratory ...
via Bing News